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Review
Association between progestin-only
contraceptive use and cardiometabolic
outcomes: A systematic review and
meta-analysis
Marija Glisic1, Sara Shahzad2, Stergiani Tsoli3,4,
Mahmuda Chadni5, Eralda Asllanaj1, Lyda Z Rojas1,
Elizabeth Brown5, Rajiv Chowdhury2, Taulant Muka1
and Oscar H Franco1
Abstract
Aims: The association between progestin-only contraceptive (POC) use and the risk of various cardiometabolic out-
comes has rarely been studied. We performed a systematic review and meta-analysis to determine the impact of POC
use on cardiometabolic outcomes including venous thromboembolism, myocardial infarction, stroke, hypertension and
diabetes.
Methods and results: Nineteen observational studies (seven cohort and 12 case–control) were included in this
systematic review. Of those, nine studies reported the risk of venous thromboembolism, six reported the risk of
myocardial infarction, six reported the risk of stroke, three reported the risk of hypertension and two studies reported
the risk of developing diabetes with POC use. The pooled adjusted relative risks (RRs) for venous thromboembolism,
myocardial infarction and stroke for oral POC users versus non-users based on the random effects model were 1.06
(95% confidence interval (CI) 0.70–1.62), 0.98 (95% CI 0.66–1.47) and 1.02 (95% CI 0.72–1.44), respectively. Stratified
analysis by route of administration showed that injectable POC with a RR of 2.62 (95% CI 1.74–3.94), but not oral POCs
(RR 1.06, 95% CI 0.7–1.62), was associated with an increased risk of venous thromboembolism. A decreased risk of
venous thromboembolism in a subgroup of women using an intrauterine levonorgestrel device was observed with a RR
of 0.53 (95% CI 0.32–0.89). No effect of POC use on blood pressure was found, but there was an indication for an
increased risk of diabetes with injectable POCs, albeit non-significant.
Conclusions: This systematic review and meta-analysis suggests that oral POC use is not associated with an increased
risk of developing various cardiometabolic outcomes, whereas injectable POC use might increase the risk of venous
thromboembolism.
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Introduction
A number of studies have debated the association
between combined oral contraceptive use and the risk
of cardiometabolic outcomes,1–3 with some studies
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reporting an increased risk of venous thromboembol-
ism (VTE), stroke and myocardial infarction (MI) for
users of combined oral contraceptives (COCs).3,4 COCs
can aﬀect lipid proﬁles, carbohydrate metabolism,
haemostatic factors and thrombolysis, and this may
be the pathway by which they aﬀect the risk of develop-
ing various cardiometabolic outcomes.5–8. It has been
postulated that the increased risk of various cardiome-
tabolic outcomes is mainly attributed to the oestrogen
content of these contraceptives,9 while the role of
exogenous progestins in modulating the oestrogenic
eﬀects remains controversial.10 Therefore, over the
years the oestrogen content of combined oral contra-
ceptive pills has decreased and new oral contraceptives
with progestin-only content have been developed,
which are considered to be safer.9 The type of progestin
as well as the route of administration are important
factors in predicting the risk of various cardiometabolic
outcomes. Progestins such as gestodene, norgestimate
and desogestrel have been associated with a greater
VTE risk than the older progestins (levonorgestrel,
lynestrenol, norethisterone).11 Also, studies have
reported an elevated risk of VTE with the use of
depot medroxyprogesterone (DMPA), which has a rela-
tively higher dose of progestin.12,13 Weight gain is cited
as a common side eﬀect and is a major reason for dis-
continuation of DMPA.14 Previous studies have gener-
ally found no association between the use of injectable
or implantable progestin-only contraceptives (POCs)
and the development of glucose intolerance;15 however,
epidemiological evidence has suggested a possible
increased risk of diabetes among DMPA users.15 A
rise in blood pressure as a side eﬀect of combined
oral contraceptives has been theorised to be the critical
mechanism for increased cardiovascular risk in women
on COCs; however, the evidence on the eﬀect of POCs
on blood pressure remains limited.16 To date, there is
scarce evidence on how POCs aﬀect the various cardi-
ometabolic outcomes, which might be because of the
low occurrence of chronic diseases among women of
reproductive age, and therefore low statistical power
to estimate the reliable risk due to the usage of
POCs.16 Although few reviews have evaluated the role
of POCs and the risk of VTE, stroke and MI,11,16–19
these reviews have some limitations. They are focused
on speciﬁc outcomes (MI or VTE or stroke), include
only speciﬁc study designs (case–control only), search
available literature only within a few databases and are
non-quantitative or largely non-systematic in nature.
Therefore, an updated and comprehensive quantitative
review is important, given the diﬀerent types of cardi-
ometabolic outcomes that may be aﬀected by POC use
by women of child-bearing age.
This systematic review and meta-analysis aims to
investigate the impact of POC use on the risk of
developing various cardiometabolic outcomes such as
MI, stroke, VTE, diabetes and hypertension.
Methods
Data sources and search strategy
The Cochrane Handbook for Systematic Reviews of
Interventions and PRISMA and MOOSE guidelines
were used to guide the conduct and reporting of this
review.20,21 We conducted a literature search of articles
from the following electronic databases from the earliest
record to 16 January 2017: PubMed, Web of Science
and EMBASE. The search strategy was built based on
the PICO strategy and followed the recommendations
of the Cochrane Review for progestin-only pills.22
The following key words were searched: ‘progesterone
only pill’, ‘progesterone’, ‘progestin only’, ‘progestogen
only’, ‘cardiovascular disease’, ‘heart disease’, ‘cerebro-
vascular disease’, ‘stroke’, ‘myocardial infarction’, ‘cor-
onary artery disease’, ‘venous thromboembolism’,
‘diabetes’ and ‘hypertension’. In addition, reference
lists of the included studies and relevant reviews,
as well as studies that have cited these articles, were
searched with Elsevier’s Scopus, the largest abstract
and citation database. The detailed master search strat-
egy is shown in Supplementary Figure 1.
During the ﬁrst phase of screening, two reviewers
evaluated the titles and abstracts against the inclusion
and exclusion criteria. For each potentially eligible
study, two reviewers independently assessed the full
text. In cases of disagreement, a decision was made
by consensus or, if necessary, a third reviewer was
consulted.
Study selection and eligibility criteria
Studies were included if they met all of the following
inclusion criteria: (a) used a randomised trial, case–
control, cohort (prospective or retrospective), or
cross-sectional study design; (b) reported the presence
of a treatment arm featuring the use of POCs; (c)
reported the use of progestin for the purpose of contra-
ception only; (d) collected data on the incidence of car-
diovascular disease (MI, stroke, heart disease, VTE
events), diabetes and hypertension; and (e) were based
on human data only and reported odds ratio or relative
risk (RR) comparing the use of POCs with non-users of
contraceptives.
Data extraction
Two reviewers independently extracted data and con-
sensus was reached in the case of any inconsistency with
involvement of a third reviewer. A piloted data
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extraction form was used. This included data on: study
size; study design; baseline population; location; age at
baseline; duration of follow-up; reported degree of
adjustment; type of POC use; type and numbers of out-
comes; how outcomes were ascertained; and reported
risk ratios. In instances of multiple publications, the
most up-to-date information was extracted.
Assessing the risk of bias
Bias within each individual study was evaluated by two
independent reviewers using the validated Newcastle–
Ottawa scale, a semi-quantitative scale designed to
evaluate the quality of non-randomised studies.23
The assessment of study quality was based on the selec-
tion criteria of participants, comparability of cases and
controls, and exposure and outcome assessment.
Studies that received a score of nine stars were judged
to be at low risk of bias; studies that scored seven or
eight stars were considered at medium risk; those that
scored six or less stars were considered at high risk of
bias. Detailed information on the assessment of study
quality and risk of bias is provided in Supplementary
Tables 1 and 2.
Patient involvement
Patients were not involved in our study.
Statistical analysis
We estimated the risk ratio of cardiovascular diseases
(VTE, MI and stroke) for users of POCs versus non-
users in subgroups according to the route of adminis-
tration (oral, injectable and intrauterine). Based on
previous reports estimating the yearly incidence of
those events to about 0.06% per year,24 we considered
that cardiovascular events had a low incidence (<10%
a year) in women aged less than 50 years taking oral
contraceptives. For infrequent events, the RR and odds
ratio are considered equivalent measures of RR.25,26
For initial disease risks of 10% or less, even odds
ratios of up to eight can reasonably be interpreted as
RRs.27 For each study, we used the most adjusted RR
with its 95% conﬁdence interval (CI) and we used the
inverse variance weighted method to combine RRs to
produce a pooled RR using random-eﬀects meta-ana-
lysis models, to allow for between-study heterogeneity.
We also conducted sensitivity analyses using ﬁxed
eﬀects models and we present the results in the forest
plots. Furthermore, when a study reported more than
one risk estimate, the pooled RR was obtained using a
ﬁxed-eﬀects model. A narrative synthesis and construc-
tion of descriptive summary tables were performed for
those study outcomes that could not be quantitatively
pooled. Heterogeneity was quantiﬁed using the I2 stat-
istic, classiﬁed as low (I2 25%), moderate (I2> 25%
and <75%), or high (I2 75%).28 In addition, the
Q statistic was used to assess the presence of heterogen-
eity. PQ statistic 0.05 was considered to indicate no sig-
niﬁcant heterogeneity among the included studies.
Publication bias was assessed through a funnel plot
and asymmetry was assessed using the Egger’s test.
It was not feasible to perform sensitivity analyses due
to the small number of included studies. All tests were
two-tailed and P values of 0.05 or less were considered
signiﬁcant. STATA 14 (Stata Corp, College Station,
TX, USA) was used for all statistical analyses.
Results
Study identification and selection
A total of 9898 references were identiﬁed: 2688 from
PubMed, 3198 from Web of Science, 460 from
EMBASE and 3552 from the search in Elsevier’s
Scopus (Figure 1). Of these, 5210 duplicates were
removed, and 4290 were excluded after review of the
titles and abstracts, leaving 398 articles for full-text
screening. After full-text assessment 19 articles were
included in this review. Of these studies, two were
nested case–control studies, 10 case–control studies
and seven cohort studies. No randomised clinical trial
was found. Nine studies reported the risk of VTE, six
studies reported the risk of MI, six reported the risk of
stroke, three reported the risk of hypertension and two
studies reported the risk of developing diabetes.
Characteristics of included studies
In total, 19 studies were included in this review, includ-
ing data from 62,088 women of which 11,930 women
reported using POCs. The majority of the included stu-
dies were conducted in Europe (n¼ 12) followed by the
USA (n¼ 5). In addition, there were two multi-country
studies. The age of participants ranged from 15 years to
about 66 years. Fifteen studies reported on POCs
administered orally, and ﬁve studies by injection,
implant or intrauterine device (IUD).
POC use and risk of VTE
POC use and the risk of VTE were reported in nine
articles,12,13,29–35 four of which were retrospective
case–control studies, two were nested case–control stu-
dies and three were cohort studies. The details on study
participants can be found in Supplementary Table 3.
Eight studies investigated the risk of VTE with oral,
two studies with intrauterine and three with injectable
POCs. Therefore, we have estimated the fully adjusted
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(as reported in studies) risk ratio of VTE for POC
users versus non-users in each subgroup according
to the route of administration (oral, injectable and
intrauterine).
Pooled fully adjusted risk ratios, based on more than
500 women using POCs and 176 VTE events, showed
no signiﬁcant association of oral POC use with the risk
of VTE when comparing users with non-users (pooled
risk ratio 1.06, 95% CI 0.7–1.62). There was no evi-
dence of high between-study heterogeneity for POC
use and the risk of VTE in these studies (I2¼ 36.5%
and PQ statistic¼ 0.14). Only three case–control studies
reported the risk of VTE with injectable (72 controls,
78 cases) and two studies reported on intrauterine
(125 controls and 64 cases) progestin administration.
The pooled risk ratio of VTE for users of intrauterine
POC formulation (levonorgestrel) was 0.53 (95% CI
0.32–0.89), I2¼ 10.7% and PQstatistic¼ 0.29. On the
other hand, the RR of VTE for injectable progestin
formulation (DMPA) was 2.62 (1.74–3.94), I2¼ 0%
and PQstatistic¼ 0.53 (Figure 2).
POC use and risk of MI
Six studies reported the risk of MI with POC use30,36–40
(Supplementary Table 4). Of those, ﬁve were case–
control studies and one was a cohort study. Five
studies reported RR after oral POC administration,
two studies reported RR in women using progestin
implants and one study reported RR of MI after inject-
able and intrauterine POC administration.
The adjusted RR of MI for users of POCs versus
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Figure 1. Flow diagram of studies included in the review.
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non-users varied from 0.5 to 3.5, none of the studies
reporting a statistically signiﬁcant association. Pooled
results for the fully adjusted models, based on more
than 150 women using POCs and 47 MI cases,
showed that there was no signiﬁcant association of
MI risk with those who used POCs orally versus
those who did not use hormone therapy (pooled risk
ratio 0.98, 95% CI 0.66–1.47) (Figure 3). In addition,
there was no evidence of between-study heterogeneity
for POC use and risk of MI in these studies (I2¼ 0%
and PQ statistic¼ 0.72). The pooled RR for MI in
the subgroup of women using progestin other than
orally was 1.10 (95% CI 0.77–1.56), I2¼ 0% and
PQ statistic¼ 0.65.
POC use and risk of stroke
Six studies examined the association between POC
use and the risk of stroke30,37,39–42 (Supplementary
Table 5). Of those, ﬁve were case–control studies and
one was a cohort study. The adjusted RR of stroke for
users of POCs versus non-users varied from 0.89 to 1.6,
none of the studies reporting a statistically signiﬁcant
association. The summary measure from pooled ana-
lysis including 350 women using progestin contracep-
tives orally and 199 stroke events showed no signiﬁcant
evidence to suggest that the use of POCs is associated
with the risk of stroke (pooled risk ratio 1.02, 95% CI
0.72–1.44) for the fully adjusted model (Figure 4).
There was no evidence of between-study hetero-
geneity for stroke risk and POP use (I2¼ 0% and
PQ statistic¼ 0.99). The pooled RR of stroke in women
using POCs other than orally was 0.78 (95% CI 0.6–1),
I2¼ 0% and PQ statistic¼ 0.79.
POC use and risk of hypertension
Only three cohort studies were found to report the
impact of POC use with the risk of developing hyper-
tension43–45 (Supplementary Table 6). A study by
Spellacy and Birk et al.43 followed 415 predominantly
American black women for 2 years and reported that
those who used POCs had a signiﬁcant drop in dia-
stolic blood pressure (P< 0.05). However, most of the
women in this study were 4 weeks postpartum, and
subsequently using mini pills as a contraceptive
method, which might present a bias in case selection.
However, two studies44,45 of 119 and 593 participants,
respectively, reported that POC use had no signiﬁcant
eﬀect on blood pressure. These studies were limited by
small sample size, inadequate adjustment for confoun-
ders and lost to follow-up bias.
Author,
year of publication Location
Oral
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Vlieg, 2010
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1.20 (0.40, 3.63)
0.80 (0.40, 1.90)
0.80 (0.20, 3.90)
0.68 (0.28, 1.66)
0.51 (0.23, 1.14)
1.30 (0.50, 3.00)
3.40 (0.80, 7.10)
1.82 (0.79, 4.22)
1.04 (0.75, 1.44)
1.06 (0.70, 1.62)
0.60 (0.40, 1.00)
0.30 (0.10, 1.10)
0.55 (0.36, 0.84)
0.53 (0.32, 0.89)
2.20 (1.30, 4.00)
2.19 (0.66, 7.26)
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2.62 (1.74, 3.94)
2.62 (1.74, 3.94)
1
Figure 2. The association between progestin-only contraceptive (POC) use and risk of venous thromboembolism by route of
administration. The summary estimates presented were calculated using random effects and fixed effects models. 95% confidence
interval (CI) (bars). P comes from Q statistics.
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POC use and risk of diabetes
We found two epidemiological studies that investigated
the association between POCs and the risk of
developing type 2 diabetes (T2D). A case–control
study by Kim et al.46 reported the association of POC
use and the risk of developing T2D in a health centre in
the USA (Supplementary Table 7). Diabetic cases
Author,
year of publication Location Study design
No. of cases
in POC users POC type ES (95 %CI)
Europe
Europe
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UK
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Case-control Progestogen 1.48 (0.60, 3.65)
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Petitti, 1998 USA
33Cohort
Heinemann, 1999
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7
Figure 3. The association between oral progestin-only contraceptive (POC) use and risk of myocardial infarction by route of
administration. The summary estimates presented were calculated using random effects and fixed effects models. 95% confidence
interval (CI) (bars). P comes from Q statistics.
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Figure 4. The association between oral progestin-only contraceptive (POC) use and risk of stroke by route of administration. The
summary estimates presented were calculated using random effects and fixed effects models. 95% confidence interval (CI) (bars). P
comes from Q statistics.
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(n¼ 284) and non-diabetic controls (n¼ 570) were
matched by age. It was found that users of POCs
(DMPA) were at an increased risk of developing dia-
betes compared to those who used combined pills (oes-
trogen–progestogen), odds ratio 3.6 (95% CI 1.6–7.9),
after adjusting for age and body mass index (BMI).
When compared with no history of hormonal contra-
ceptive use, POCs were still associated with the risk of
developing diabetes, odds ratio 2.1 (95% CI 1.03–4.2),
when adjusted for age, BMI and parity. However, fur-
ther adjustment for gestational diabetes diagnosed after
contraceptives given attenuated and abolished the asso-
ciation, odds ratio 1.6 (95% CI 0.77–3.5). In a cohort
study,47 Norplant users (n¼ 7977) were prospectively
compared with age-matched, non-hormonal IUD
users (n¼ 6625) and women who underwent sterilisa-
tion (n¼ 1419). Twelve T2D cases were identiﬁed – nine
in Norplant initiators (eight current users), two in IUD
initiators (three current IUD users) and one in a ster-
ilised woman. The crude incidence rate was higher in
current Norplant users compared with controls, but the
crude and adjusted rate ratios for Norplant users com-
pared with controls were not signiﬁcantly diﬀerent.
After adjusting for clinic, age and body weight, the cur-
rent implant users did not have a signiﬁcantly higher
incidence of T2D compared with the group using IUD
or sterilisation, RR 2.4 (95% CI 0.7–8.1).
Study quality and publication bias
Three studies were classiﬁed as having a low risk of
bias, ﬁve as having a medium risk of bias and the rest
were classiﬁed as having a high risk of bias. We did not
ﬁnd evidence for publication bias from the funnel plots
of VTE, MI and stroke, as shown in Supplementary
Figure 2.
Discussion
Overall, the available body of literature suggests that
the use of oral POCs is not associated with an excess
risk of VTE, MI, stroke and hypertension. We found
limited evidence that DMPA is associated with an
increased risk of VTE, while intrauterine application
of levonorgestrel was associated with a decreased risk
of VTE. There was, also, an indication for an increased
risk of diabetes with injectable POCs, albeit non-
signiﬁcant.
Our ﬁndings suggest no eﬀect on VTE risk after oral
POCs and a decreased risk of VTE in a subgroup of
women using an intrauterine levonorgestrel device with
RR 0.53 (95% CI 0.32–0.89). However, the subgroup
analysis based on three studies,13,34,40 including 78 VTE
events, showed a 2.6-fold increased risk of VTE for
injectable progestin users compared to non-users.
A study that contributed most to the summary statistic
for DMPA and the risk of VTE excluded women in
highest risk of VTE (personal history of VTE);12 there-
fore, it is less likely that the eﬀect observed on injectable
progestin is due to confounding by indication. POC
intake causes a decrease in sex hormone-binding globu-
lin, which is a marker of venous thrombosis risk, and
this eﬀect varies with the dose and type of progestogen
used.48,49 Indeed, the plasma concentration of levonor-
gestrel with IUD ranges between 74 and 166 pg/mL,50
while after an intramuscular injection of 150mg
of DMPA, the peak plasma concentration is 2500–
7000 pg/mL and remains greater than 430 pg/mL at 3
months.51,52 Also, progestins may express prothrombo-
tic properties by modulation of protein C resistance,53
by aﬀecting the cellular expression of tissue factor
and circulating tissue factor pathway inhibitor.54,55
The third generation progestins (e.g. desogestrel) are
suggested to be more prothrombotic than earlier for-
mulations such as levonorgestrel or norethisteron.11
Levonorgestrel does not increase activated protein C
resistance, suggesting that this contraceptive does not
have a prothrombotic eﬀect.53 While, for instance, in a
mouse model of vascular injury, medroxyprogesterone
increased thrombin formation and changes in vascular
gene expression, resulting in altered plaque matrix
either alone and in combination with oestradiol.56
A previous meta-analysis of six case–control studies
reported that there was no increase in the MI risk with
POC use.17 In our meta-analysis we excluded one of the
studies included in previous estimates, as it was inves-
tigating the eﬀect of COCs (contained up to 50 mg of
oestrogen combined with a ﬁxed dose of progestin),57
and was not a progestin-only pill; however, our results
were in line with previous ﬁndings. The result was simi-
lar according to the route of administration, including
implant, injectable and oral POCs. Furthermore, our
ﬁndings are in line with a previous meta-analysis of
six case–control studies18 showing that POC use had
no signiﬁcant eﬀect on the risk of developing stroke.
Similarly, a systematic review looking at the association
of POC use with high blood pressure also concluded
that POC use does not aﬀect diastolic and systolic
blood pressures.16 However, all of the included studies
were written in the 1970s and 1980s; therefore, they
have investigated the ﬁrst and second generations of
POCs, while the information on the third generation
of progestins is lacking. Furthermore, an important
limitation of these studies is the fact that they investi-
gated POC use in normotensive women, yet future stu-
dies should investigate the eﬀects of POCs on blood
pressure in women with a history of hypertension.
A case–control study conducted among Navajho
women showed that use of injectable POCs signiﬁcantly
increased the risk of developing T2D when adjusted for
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age, BMI and parity; however, after further adjustment
for gestational diabetes diagnosed after contraceptives
given, the association was attenuated and not any more
signiﬁcant.46 Women with gestational diabetes are at
higher risk of developing T2D, and women who used
DMPA were signiﬁcantly more likely to have a history
of gestational diabetes.46 Therefore, it might be that
gestational diabetes is on the pathway between POC
use and T2D development, which needs further inves-
tigation. Nevertheless, a study conducted in breast-
feeding Latina women with previous gestational
diabetes mellitus demonstrated that oral POCs were
associated with an increased risk of diabetes compared
with an equal use of low-dose combination oral contra-
ceptives, indicating that if an association between POC
use and diabetes exists pathways other than gestational
diabetes may be present.58 In this study, however, low-
dose progestin and COCs were not associated with risk
of diabetes.58 The mechanism linking POC use with a
potential increased risk of diabetes is unknown. A pos-
sible mechanism might be the adverse eﬀect that POC
use has on obesity, which is an important risk factor for
diabetes.46 The 2016 Cochrane review investigated the
association between POC use and weight changes.59
Although the actual mean weight gain was generally
low (<2 kg for most studies) for 6–12 months of
follow-up, the eﬀect on weight varied with diﬀerent
formulations and routes of POC administration, being
more pronounced with DMPA.14,60–62 Furthermore,
using contraception reduces the numbers of pregnan-
cies, which is also considered to be a risk factor for
developing diabetes.46 Also, a decrease in sex-
hormone-binding globulin is associated with injectable
DMPA,63 and low circulating levels of sex hormone-
binding globulin are a strong predictor of the risk of
T2D in women and men.64 The other possibility is that
women taking COCs compared to those receiving
DMPA are healthier and have a lower risk of develop-
ing T2D.46 Indeed, a systematic review on studies in
non-diabetic women based on six studies investigating
DMPA use reported an elevation of insulin concentra-
tion (compared with baseline before DMPA) at 2–3
hours after the glucose challenge;15 however, most of
the studies included in the review did not ﬁnd any eﬀect
of injectable contraceptives on glucose concentrations
in lean glucose-tolerant women. Studies that reported
increased glucose were performed in subjects who had
greater baseline body weight or had a longer duration
of POC use.15
Strengths and limitations
Our results are consistent with previously published
reviews;11,16–19 however, this is the ﬁrst systematic
review and meta-analysis that looks at the association
of POC use with multiple cardiometabolic outcomes
such as VTE, MI, stroke, hypertension and diabetes.
Nevertheless, there are number of limitations to this
review. First, typical with any literature-based review,
it is possible that both measured and unmeasured pub-
lication bias can limit our overall ﬁndings. Although
evaluations with the conventional funnel plots and
Egger test estimates indicate minimal publication bias,
these approaches are limited by a qualitative assessment
reliant on visual inspection and the fact that the major-
ity of these assessments were based on a limited number
of studies. Thus we cannot exclude the possibility of
publication bias coming from the underreporting of
negative ﬁndings (increased risk of cardiovascular out-
comes with POC use). Such a scenario would lead
towards null ﬁndings and an underestimation of our
ﬁndings. The studies included in this review were
limited by study design and methodology: (a) all studies
were observational in nature and thus prone to bias
and confounding; (b) they had small numbers of
participants using POCs, which explains the wide CIs
of some of the studies; and (c) studies did not specify
the type and dosage of POCs or the type and
dosage of POCs varied considerably. Also, even
though the prevalence of intermediate risk factors
for cardiovascular disease is low among women
of reproductive age, 10% of women aged 18–44 years
have high blood pressure, while 15% of women
aged 20–45 years have high cholesterol, also 3%
of women of reproductive age have T2D.65,66
Although the majority of studies included in our
review adjust for potential confounding and intermedi-
ate cardiovascular risk factors, they do not adjust
for medication use (e.g. statins, antihypertensive
medications). Therefore, future studies should take
this into account when investigating the risk of diabetes
with POC use.
Implications for policy and future research
European guidelines on cardiovascular disease preven-
tion in clinical practice have emphasised the role of the
cardiologist in screening for cardiovascular disease risk
factors and assessing the baseline cardiovascular risk
before advising the type of contraceptives to be
used.67 US medical eligibility criteria for contraceptive
use advocates the use of POCs for women at high risk
of cardiovascular disease,68 which may be a safe recom-
mendation as also supported by our ﬁndings of no
association between oral POC use and VTE, MI and
stroke in women in general. Although the US medical
eligibility criteria for contraceptive use68 recognises
a previous history of MI and stroke as well as hyper-
tension as contraindications for injectable POC use,
a previous history of VTE is not recognised
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as a contraindication for DMPA. Therefore, based on
our ﬁndings of an increased risk of developing VTE and
present indication of an increased risk of T2D, further
investigation is required in order to rule out potential
harmful eﬀects of DMPA in these women.
Conclusions
In conclusion, studies included in this meta-analysis
suggest that POC use is not associated with an
increased risk of developing various cardiometabolic
outcomes. However, our ﬁndings, based on limited evi-
dence, suggest that an increased risk of VTE might be
present for injectable POCs, as well as some indication
for an increased diabetes risk. Also, there is some indi-
cation that an intrauterine levonorgestrel device might
be a safe choice with regard to VTE risk. Nevertheless,
this systematic review must be interpreted with caution
as the studies included in the review were observational
in nature and meta-analyses results were based on stu-
dies with a small sample size. Rigorous studies with
better quality design and lower risk of bias are needed
to determine the true impact of POC use on various
cardiometabolic outcomes.
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